Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARIL-RA-EASY: Sarilumab Auto-Injector Usability in RA
NCT02057250Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2014
- Primary completion
- Feb 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of sarilumab in rheumatoid arthritis (RA) (4 arms), sponsored by Sanofi. Primary endpoint: Number of Validated AID Associated Product Technical Failures (PTFs) at Week 12. Started Mar 2014; status: completed.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02057250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057250.